why choose us

First received: January 12, 2023

Clinical Trial: Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Study Status: Completed

Recruit Status: RECRUITING

Condition: Epstein-Barr Virus Infection

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-Seronegative Pe

Brief Summary: Background:Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono).Mono can cause fatigue that lasts more than 6 months, and some people can have severe complications.EBV infection may also contribute to some cancers and autoimmune diseases.Currently, there are no approved therapies or vaccines for EBV infection.Objective:To test a vaccine against EBV.Eligibility:Healthy people aged 18 to 22 years.Design:Participants will be screened in 2 parts.They will have a blood test.If that test shows…

Read more